C WorldWide Group Holding A S Buys 1,873 Shares of Cencora, Inc. $COR

C WorldWide Group Holding A S lifted its position in Cencora, Inc. (NYSE:COR) by 39.7% in the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,588 shares of the company’s stock after purchasing an additional 1,873 shares during the period. C WorldWide Group Holding A S’s holdings in Cencora were worth $2,070,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Kemnay Advisory Services Inc. bought a new stake in Cencora during the 4th quarter valued at $25,000. Oakworth Capital Inc. purchased a new stake in shares of Cencora in the 4th quarter worth $26,000. Elyxium Wealth LLC bought a new position in shares of Cencora during the 4th quarter worth $27,000. Archer Investment Corp grew its position in shares of Cencora by 134.3% during the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after buying an additional 47 shares in the last quarter. Finally, Motiv8 Investments LLC purchased a new position in shares of Cencora during the fourth quarter valued at $29,000. Institutional investors own 97.52% of the company’s stock.

Cencora Trading Up 3.8%

Shares of NYSE COR opened at $307.80 on Friday. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59. The stock has a market capitalization of $59.88 billion, a P/E ratio of 23.60, a price-to-earnings-growth ratio of 1.65 and a beta of 0.58. Cencora, Inc. has a 1-year low of $244.82 and a 1-year high of $377.54. The business has a fifty day moving average price of $279.05 and a 200 day moving average price of $317.75.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.07). The company had revenue of $78.36 billion during the quarter, compared to analysts’ expectations of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. Cencora’s revenue for the quarter was up 3.9% on a year-over-year basis. During the same quarter last year, the firm earned $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Equities research analysts expect that Cencora, Inc. will post 17.79 EPS for the current fiscal year.

Cencora declared that its board has initiated a stock buyback program on Thursday, May 21st that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the company to repurchase up to 3.9% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s management believes its shares are undervalued.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were given a $0.60 dividend. The ex-dividend date of this dividend was Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.8%. Cencora’s payout ratio is presently 18.40%.

Insider Activity

In other news, Director Lauren M. Tyler acquired 550 shares of Cencora stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average price of $270.23 per share, for a total transaction of $148,626.50. Following the purchase, the director directly owned 4,359 shares in the company, valued at $1,177,932.57. The trade was a 14.44% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. 0.38% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research firms recently weighed in on COR. UBS Group lifted their price objective on Cencora from $410.00 to $412.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Robert W. Baird dropped their target price on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Bank of America raised their target price on shares of Cencora from $280.00 to $285.00 and gave the company a “neutral” rating in a research report on Wednesday, June 24th. Weiss Ratings cut shares of Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, June 30th. Finally, William Blair started coverage on shares of Cencora in a research note on Tuesday, April 28th. They set a “market perform” rating on the stock. Eleven research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $367.75.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.